Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Outcomes in Clinical Trials Evaluating Interventions for the Prevention and Treatment of Hepatic Encephalopathy

Research output: Contribution to journalReviewResearchpeer-review

  1. The role of Branched Chain Amino Acids in the treatment of hepatic Encephalopathy

    Research output: Contribution to journalReviewResearchpeer-review

  2. Cerebral Blood Flow and Metabolism in Hepatic Encephalopathy-A Meta-Analysis

    Research output: Contribution to journalReviewResearchpeer-review

  1. Energy expenditure and loss of muscle and fat mass in patients with walled-off pancreatic necrosis: A prospective study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Modified Marshall Score Predicts Mortality in Patients With Walled-off Pancreatic Necrosis Treated in an Intensive Care Unit

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The cost of endoscopic treatment for walled-off pancreatic necrosis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Randomised clinical trials and systematic reviews of research findings can provide high-quality evidence for decision-making in the management of patients with hepatic encephalopathy. A large number of clinical trials have been undertaken, over the last 50 years, relative to the prevention and treatment of this condition. However, changes have been made, during this time, in the classification of hepatic encephalopathy, diagnostic criteria and assessment measures. These temporally based changes and the consequent lack of standardisation make it difficult to compare interventions and to evaluate their comparative efficacy and safety. While some consensus has been reached in relation to the diagnostic evaluation, classification and monitoring of patients in clinical trials, there is less surety about the choice of clinical endpoints. These outcome measures should be universally applicable, easily measured and clinically relevant. This article reviews the current recommendations regarding outcome selection and outlines some of the potential problems and pitfalls inherent in clinical trial evaluating interventions for the management of hepatic encephalopathy.

Original languageEnglish
JournalJournal of Clinical and Experimental Hepatology
Volume9
Issue number3
Pages (from-to)354-361
Number of pages8
ISSN0973-6883
DOIs
Publication statusPublished - May 2019

    Research areas

  • cirrhosis, mortality, risk-benefit, serious adverse events, surrogate markers

ID: 57714670